國藥現代(600420.SH):地氯雷他定糖漿獲得藥品註冊證書
格隆匯12月6日丨國藥現代(600420.SH)公佈,近日,公司控股子公司致君坪山收到國家藥品監督管理局核准簽發的“地氯雷他定糖漿”藥品註冊證書。
地氯雷他定是一種非鎮靜的長效組胺拮抗劑,主要用於緩解慢性特發性蕁麻疹及過敏性鼻炎的全身及局部症狀。根據PDB數據庫顯示,2020年地氯雷他定全球市場的銷售額達到5.82億美元,2020年國內樣本醫院銷售額達人民幣3.25億元。目前該產品糖漿劑主要生產廠家包括萬特製藥(海南)有限公司、湖北康源藥業有限公司、四川成都同道堂製藥有限責任公司、江蘇廣承藥業有限公司等。截至目前,致君坪山地氯雷他定糖漿(60ml:30mg)項目累計研發投入約人民幣730.00萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.